En­her­tu strikes again with a PhI­II suc­cess in an­oth­er breast can­cer pop­u­la­tion

An­oth­er sum­mer day, an­oth­er En­her­tu up­date.

The As­traZeneca-Dai­ichi Sankyo an­ti­body-drug con­ju­gate has passed an­oth­er tri­al, this time a Phase III tri­al test­ing the can­cer drug ver­sus physi­cian’s choice in pa­tients with HER2-pos­i­tive metasta­t­ic breast can­cer.

The DES­TINY-Breast02 study beat out the oth­er treat­ments — trastuzum­ab/capecitabine or la­p­a­tinib/capecitabine — in im­prov­ing pro­gres­sion-free sur­vival and a sec­ondary end­point, over­all sur­vival.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER